The Mednet Secured a $2M Contract from NCI for AI-Driven Clinical Trial Platform
The Mednet has been awarded a $2M contract by the National Cancer Institute to develop an AI-based platform to revolutionize clinical trial search and improve enrollment and diversity.
Nadine and Samir Housri founded the Mednet, inspired by their family’s experience when their father was diagnosed with cancer. With Nadine’s oncology background and a network of expert physicians, they quickly accessed specialized knowledge beyond textbook information, which informed critical treatment decisions.
Recognizing that much valuable knowledge remains undocumented and inaccessible to other physicians, they envisioned a platform for sharing practical clinical insights. This led to the creation of the Mednet, initially focused on oncology and later expanding to twelve additional specialties.
Today, the Mednet connects over 20,000 physicians, including 1,700 experts from leading academic institutions, providing access to more than 15,600 peer-reviewed clinical QandAs. Their journey not only helped their father’s care team make informed decisions but also aims to support physicians everywhere in improving patient care.
The Mednet, the leading question-and-answer platform for physicians, has been awarded a $2 million contract by the National Cancer Institute (NCI) to develop an AI-based platform focused on increasing physician engagement in cancer clinical trials and enhancing diversity among participants.
This innovative solution builds on The Mednet’s extensive online community, which is utilized by over 85% of U.S. oncologists. It employs advanced AI techniques to match physician inquiries with relevant clinical trials, improving patient access to potentially life-saving therapies.
Dr. Nadine Housri, Co-founder and Chief Medical Officer of theMednet, stated,
“This is a completely new paradigm for how doctors learn about clinical trials, aligning more closely with their practice. theMednet will allow doctors to ask clinical questions and receive related trial options.”
The platform will provide real-time, personalized trial recommendations based on physicians’ specialties, locations, and patient demographics. Brian Adams, Chief Technology Officer of the Mednet, emphasized the importance of this approach, noting that traditional clinical trial searches are often time-consuming and complex. By leveraging AI advancements, the Mednet aims to streamline the search process and enhance the enrollment of diverse patient populations.
For more information, visit oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023